Peptide News Digest

#Doustdar

2 stories

Industry · View digest

Wegovy Pill Surpasses 1 Million US Users 16 Weeks Post-Launch — Novo CEO Doustdar

Novo Nordisk CEO Mike Doustdar confirmed on the May 6 Q1 analyst call and in May 14 follow-up commentary that the Wegovy pill has surpassed 1 million cumulative US users 16 weeks after the January 5, 2026 launch. The pill posted DKK 2.26B (~$354M) in Q1 sales (nearly 2x analyst consensus) on roughly 1.3 million Q1 prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions per the Q1 IQVIA data. International expansion is targeted for H2 2026 with EU approval anticipated before year-end. The pill ramp is the cleanest near-term commercial signal for Novo against Lilly's tirzepatide franchise (Mounjaro/Zepbound), which displaced Keytruda as the world's #1 best-selling drug in Q1 2026.

Industry · View digest

Novo Nordisk Q1 May 6 Detail: Wegovy at 65% of US New GLP-1 Prescriptions — CEO Calls It 'Turnaround Situation'; Single-Chamber CagriSema Co-Formulation Discontinued

Novo Nordisk CEO Mike Doustdar told CNBC May 6 that the Wegovy brand now holds 65% of all new US GLP-1 prescriptions and characterized the moment as a 'turnaround situation' for the franchise. The Q1 print also disclosed that Novo has terminated the single-chamber CagriSema co-formulation project 'due to portfolio considerations' — the dual-chamber injectable system continues, with the original FDA filing already submitted and a decision expected late 2026. The CEO insisted plans for the CagriSema launch remain on track despite the device change. CNBC also documented LifeMD's new-patient volume jumping from 300–400/day before the Wegovy pill launch to 600–1,000/day after.